The vials represent a new opportunity to increase ... Lilly and Novo Nordisk, which makes the other leading anti-obesity drug ...

The vials are priced at about half of what shots ... Zepbound and Novo’s Wegovy have gone in and out of supply since they ...

Novo Nordisk's rollout of obesity therapy Wegovy has been beset by production ... by problems at a contract manufacturer used to fill vials of the drug pegged back sales following its approval ...

Both companies have been struggling to meet massive demand for their products – Zepbound and Wegovy are both on the FDA's list of medicines in short supply – and a simpler-to-produce vial ...